World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
65637
World Ranking
9063
National Ranking
4675

Overview

Joyce O'Shaughnessy is affiliated with Baylor University Medical Center in the United States. Their research primarily falls within the field of Medicine, with a focus on Oncology and several related subfields, including Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging, and Genetics.

Their work covers a range of topics in cancer research, emphasizing:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer-related Molecular Pathways

Frequent publication venues for Joyce O'Shaughnessy include:

  • Cancer Research
  • Annals of Oncology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • New England Journal of Medicine

They have collaborated extensively with co-authors such as Hope S. Rugo, Javier Cortés, Nadia Harbeck, Sara M. Tolaney, and Sara A. Hurvitz, with collaboration counts ranging from 23 to 36 joint works.

Recent notable publications include:

  • Pembrolizumab for Early Triple-Negative Breast Cancer, 2020, New England Journal of Medicine
  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, 2021, New England Journal of Medicine
  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer, 2021, Annals of Oncology
  • Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial, 2021, Annals of Oncology
  • Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer, 2024, New England Journal of Medicine

Their publications have attracted significant citations, indicating the impact and reach of their recent work in the oncology and breast cancer research communities.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

    William J. Gradishar;Sergei Tjulandin;Neville Davidson;Heather Shaw

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

    Javier Cortes;Joyce O'Shaughnessy;David Loesch;Joanne J.L. Blum

  • Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

    Kimberly L. Blackwell;Harold J. Burstein;Anna Maria Storniolo;Hope Rugo

  • Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

    Howard A. Burris;Hope S. Rugo;Svetislava J. Vukelja;Charles L. Vogel

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A Mayer;Linda T Vahdat;Sara M Tolaney

  • Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

    Gary J. Kelloff;John M. Hoffman;Bruce Johnson;Howard I. Scher

  • The Global Breast Cancer Burden: Variations in Epidemiology and Survival

    Gabriel N. Hortobagyi;Jaime de la Garza Salazar;Kathleen Pritchard;Dino Amadori

  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

    Sibylle Loibl;Joyce O'Shaughnessy;Michael Untch;William M Sikov

  • Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing

    Rebecca J. Leary;Mark Sausen;Isaac Kinde;Nickolas Papadopoulos

  • Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer

    F.A. Holmes;J.A. O’Shaughnessy;S. Vukelja;S.E. Jones

  • Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

    Kimberly L. Blackwell;Harold J. Burstein;Anna Maria Storniolo;Hope S. Rugo

  • Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

    Stephen E. Jones;Michael A. Savin;Frankie Ann Holmes;Joyce A. O'Shaughnessy

  • A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer

    Christos Hatzis;Lajos Pusztai;Vicente Valero;Daniel J. Booser

  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

    Sylvia Adams;Peter Schmid;Hope H.S. Rugo;Eric Winer

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Adam Brufsky
Adam Brufsky University of Pittsburgh
Aditya Bardia
Aditya Bardia Harvard University
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Véronique Diéras
Véronique Diéras Institute Curie
Sara A. Hurvitz
Sara A. Hurvitz Fred Hutchinson Cancer Research Center
Sara M. Tolaney
Sara M. Tolaney Harvard University
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Igor Bondarenko
Igor Bondarenko Ministry of Internal Affairs

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The journey to a healthcare career in the USA offers various alternative pathways beyond a traditional MD. Many students consider advanced nursing degrees, especially programs tailored for non-nurses. For those interested in accelerated options, direct entry msn programs for non-nurses online can be an excellent choice, helping you transition into nursing with a master’s degree even if your background isn’t in healthcare.

Admissions requirements vary widely among schools. Some prospective students search for whats the easiest nursing program to get into? to increase their chances of enrolling quickly, especially if they wish to enter the workforce soon. Similarly, students looking to avoid standardized entrance exams can explore institutions listed in do all nursing schools require the teas.

For those interested in allied health, medical billing and coding is a fast-growing field that provides remote career opportunities. The best medical billing and coding schools online offer accredited programs, often with financial aid, that make it easier to start a healthcare career from home. These diverse pathways make it possible to find a medical or healthcare career that fits your background and life goals.

Best Scientists Citing Joyce O'Shaughnessy

Trending Scientists